NNNN
What one share of Anbio Biotechnology holds
In Vitro and In Vivo Diagnostic Substances
Anbio Biotechnology is dedicated to the advancement of medical technology and the provision of in vitro diagnostics (IVD) products. Our unwavering commitment lies in transforming the diagnostics landscape on a global scale, fostering a paradigm shift towards personalized and decentralized diagnostic solutions.
Anbio Biotechnology’s numbers from its SEC filings, divided by its shares. Results cover the latest fiscal year to 2025-12-31; the balance sheet is as of 2025-12-31.
| Sales | $0.20 |
|---|---|
| Profit | $0.15 |
| Cash and investments | $0.18 |
| Book value | $0.69 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2023 | $0.31 | $0.11 | — | $0.04 | — | $0.69 |
| 2024 | $0.19 | $0.06 | — | $0.05 | — | $0.41 |
| 2025 | $0.20 | $0.15 | — | −$0.15 | — | $0.69 |